1
|
Ardourel M, Ranchon-Cole I, Pâris A, Felgerolle C, Acar N, Lesne F, Briault S, Perche O. FMR protein: Evidence of an emerging role in retinal aging? Exp Eye Res 2022; 225:109282. [PMID: 36265576 DOI: 10.1016/j.exer.2022.109282] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/11/2022] [Revised: 10/05/2022] [Accepted: 10/11/2022] [Indexed: 12/29/2022]
Abstract
Aging is a multifactorial process that affects the entire organism by cumulative alterations. Visual function impairments that go along with aging are commonly observed, causing lower visual acuity, lower contrast sensitivity, and impaired dark adaptation. Electroretinogram analysis revealed that the amplitudes of rod- and cone-mediated responses are reduced in aged mice and humans. Reports suggested that age-related changes observed in both rod and cone photoreceptor functionality were linked to oxidative stress regulation or free radical production homeostasis. Interestingly, several recent reports linked the fragile X mental retardation protein (FMRP) cellular activity with oxidative stress regulation in several tissue including brain tissue where FMRP participates to the response to stress via protein translation in neurite or is involved in free radical production and abnormal glutathione homeostasis. Based on these recent literatures, we raised the question about the effect of FMRP absence in the aging retina of Fmr1-/y compared to their WT littermates. Indeed, up to now, only young or adult mice (<6 months) were investigated and have shown a specific retinal phenotype. Herein, we demonstrated that Fmr1-/y mice do not present the aging effect on retinal function observed in WT littermates since ERG a- and b-waves amplitudes as well as oscillatory potentials amplitudes were not collapsed with age (12/18 months old). Absence of FMRP and its consequences seem to protect the retina against aging effect, rising a pivotal role of FMRP in retinal aging process.
Collapse
Affiliation(s)
- M Ardourel
- UMR7355, CNRS, Orléans, France; Experimental and Molecular Immunology and Neurogenetics, University of Orléans, 3b rue de la Ferollerie, 45071, Orléans, Cedex 2, France
| | - I Ranchon-Cole
- Université Clermont Auvergne, CHU Clermont-Ferrand, Inserm, Neuro-Dol, F-63000, Clermont-Ferrand, France
| | - A Pâris
- UMR7355, CNRS, Orléans, France; Experimental and Molecular Immunology and Neurogenetics, University of Orléans, 3b rue de la Ferollerie, 45071, Orléans, Cedex 2, France
| | - C Felgerolle
- UMR7355, CNRS, Orléans, France; Experimental and Molecular Immunology and Neurogenetics, University of Orléans, 3b rue de la Ferollerie, 45071, Orléans, Cedex 2, France
| | - N Acar
- Eye and Nutrition Research Group, Centre des Sciences du Goût et de l'Alimentation, CNRS, INRAE, Institut Agro, Université Bourgogne Franche-Comté, 21000, Dijon, France
| | - F Lesne
- Genetic Department, Regional Hospital, 14 Avenue de l'hôpital, 45100, Orléans, France
| | - S Briault
- UMR7355, CNRS, Orléans, France; Experimental and Molecular Immunology and Neurogenetics, University of Orléans, 3b rue de la Ferollerie, 45071, Orléans, Cedex 2, France; Genetic Department, Regional Hospital, 14 Avenue de l'hôpital, 45100, Orléans, France
| | - O Perche
- UMR7355, CNRS, Orléans, France; Experimental and Molecular Immunology and Neurogenetics, University of Orléans, 3b rue de la Ferollerie, 45071, Orléans, Cedex 2, France; Genetic Department, Regional Hospital, 14 Avenue de l'hôpital, 45100, Orléans, France.
| |
Collapse
|
2
|
Ardourel M, Pâris A, Felgerolle C, Lesne F, Ranchon-Cole I, Briault S, Perche O. FMRP-related retinal phenotypes: Evidence of glutamate-glutamine metabolic cycle impairment. Exp Eye Res 2022; 224:109238. [PMID: 36067823 DOI: 10.1016/j.exer.2022.109238] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2022] [Revised: 08/16/2022] [Accepted: 08/29/2022] [Indexed: 11/18/2022]
Abstract
FMRP, the fragile X mental retardation protein coded by the FMR1 gene, is an RNA-binding protein that assists transport, stabilization and translational regulation of specific synaptic mRNAs. Its expression has been found in multiple cell types of central nervous system (CNS) including glial cells where its involvement in glutamate neurotransmitter homeostasis have been shown. Indeed, glutamate homeostasis deficit has been observed in absence of FMRP in-vivo in cortex and hippocampus structures as well as in vitro on astroglial cell culture. Interestingly, the retina which is an extension of the CNS is presenting electrophysiological alterations in absence of FMRP in both human and murine models suggesting neurotransmitter impairments. Therefore, we investigate the consequences of Fmrp absence on Glutamate-Glutamine cycle in whole retinas and primary retinal Müller cells culture which are the main glial cells of the retina. Using the Fmr1-/y mice, we have shown in vivo and in vitro that the absence of Fmrp in Müller cells is characterized by loss of Glutamate-Glutamine cycle homeostasis due to a lower Glutamine Synthetase protein expression and activity. The lack of Fmrp in the retina induces a reduced flow of glutamine synthesis. Our data established for the first time in literature a direct link between the lack of Fmrp and neurotransmitter homeostasis in the retina.
Collapse
Affiliation(s)
- Maryvonne Ardourel
- UMR7355, CNRS, Orléans, France; Experimental and Molecular Immunology and Neurogenetics, University of Orléans, 3b rue de la Ferollerie, F-45071, Orléans Cedex 2, France
| | - Arnaud Pâris
- UMR7355, CNRS, Orléans, France; Experimental and Molecular Immunology and Neurogenetics, University of Orléans, 3b rue de la Ferollerie, F-45071, Orléans Cedex 2, France
| | - Chloé Felgerolle
- UMR7355, CNRS, Orléans, France; Experimental and Molecular Immunology and Neurogenetics, University of Orléans, 3b rue de la Ferollerie, F-45071, Orléans Cedex 2, France
| | - Fabien Lesne
- Genetic Department, Regional Hospital, 14 Avenue de l'hôpital, 45100, Orléans, France
| | - Isabelle Ranchon-Cole
- Université Clermont Auvergne, CHU Clermont-Ferrand, Inserm, Neuro-Dol, F-63000, Clermont-Ferrand, France
| | - Sylvain Briault
- Genetic Department, Regional Hospital, 14 Avenue de l'hôpital, 45100, Orléans, France; UMR7355, CNRS, Orléans, France; Experimental and Molecular Immunology and Neurogenetics, University of Orléans, 3b rue de la Ferollerie, F-45071, Orléans Cedex 2, France
| | - Olivier Perche
- Genetic Department, Regional Hospital, 14 Avenue de l'hôpital, 45100, Orléans, France; UMR7355, CNRS, Orléans, France; Experimental and Molecular Immunology and Neurogenetics, University of Orléans, 3b rue de la Ferollerie, F-45071, Orléans Cedex 2, France.
| |
Collapse
|
3
|
Perche O, Lesne F, Patat A, Raab S, Twyman R, Ring RH, Briault S. Large-conductance calcium-activated potassium channel haploinsufficiency leads to sensory deficits in the visual system: a case report. J Med Case Rep 2022; 16:180. [PMID: 35509069 PMCID: PMC9069818 DOI: 10.1186/s13256-022-03387-7] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2022] [Accepted: 03/27/2022] [Indexed: 12/11/2022] Open
Abstract
Background Mutations in the genes encoding the large-conductance calcium-activated potassium channel, especially KCNMA1 encoding its α-subunit, have been linked to several neurological features, including intellectual disability or autism. Associated with neurodevelopmental phenotypes, sensory function disturbances are considered to be important clinical features contributing to a variety of behavioral impairments. Large-conductance calcium-activated potassium channels are important in regulating neurotransmission in sensory circuits, including visual pathways. Deficits in visual function can contribute substantially to poor quality of life, while therapeutic approaches aimed at addressing such visual deficits represent opportunities to improve neurocognitive and neurobehavioral outcomes. Case presentation We describe the case of a 25-year-old Caucasian male with autism spectrum disorder and severe intellectual disability presenting large-conductance calcium-activated potassium channel haploinsufficiency due to a de novo balanced translocation (46, XY, t [9; 10] [q23;q22]) disrupting the KCNMA1 gene. The visual processing pathway of the subject was evaluated using both electroretinography and visual contrast sensitivity, indicating that both retinal bipolar cell function and contrast discrimination performance were reduced by approximately 60% compared with normative control values. These findings imply a direct link between KCNMA1 gene disruption and visual dysfunction in humans. In addition, the subject reported photophobia but did not exhibit strabismus, nystagmus, or other visual findings on physical examination. Conclusions This case study of a subject with large-conductance calcium-activated potassium channel haploinsufficiency and photophobia revealed a visual pathway deficit at least at the retinal level, with diminished retinal light capture likely due to bipolar cell dysfunction and an associated loss of contrast sensitivity. The data suggest that large-conductance calcium-activated potassium channels play an important role in the normal functioning of the visual pathway in humans, and that their disruption may play a role in visual and other sensory system symptomatology in large-conductance calcium-activated potassium channelopathies or conditions where disruption of large-conductance calcium-activated potassium channel function is a relevant feature of the pathophysiology, such as fragile X syndrome. This work suggests that the combined use of physiological (electroretinography) and functional (contrast sensitivity) approaches may have utility as a biomarker strategy for identifying and characterizing visual processing deficits in individuals with large-conductance calcium-activated potassium channelopathy. Trial registration ID-RCB number 2019-A01015-52, registered 17/05/2019.
Collapse
Affiliation(s)
- Olivier Perche
- Genetic Department, Centre Hospitalier Régional d'Orléans, Orléans, France.,UMR7355, Immunologie et Neurogénétique Expérimentales et Moléculaires (INEM), Centre National de la Recherche Scientifique (CNRS), Orléans, France.,Experimental and Molecular Immunology and Neurogenetics, University of Orléans, Orléans, France.,Kaerus Bioscience Ltd, London, EC1Y 4YX, UK
| | | | | | | | | | - Robert H Ring
- Kaerus Bioscience Ltd, London, EC1Y 4YX, UK.,Department of Pharmacology and Physiology, Drexel University College of Medicine, Philadelphia, PA, USA
| | - Sylvain Briault
- Genetic Department, Centre Hospitalier Régional d'Orléans, Orléans, France. .,UMR7355, Immunologie et Neurogénétique Expérimentales et Moléculaires (INEM), Centre National de la Recherche Scientifique (CNRS), Orléans, France. .,Experimental and Molecular Immunology and Neurogenetics, University of Orléans, Orléans, France. .,Kaerus Bioscience Ltd, London, EC1Y 4YX, UK.
| |
Collapse
|
4
|
Baala L, Benzekri-Lefevre D, Bret L, Kamel T, Guillaume C, Courtellemont L, El Khalil A, Guery T, Iquel S, Perche O, Khadre K, Brungs T, Decker J, Francia T, Bois J, Delamare B, Guinard J, Got L, Briault S, Boulain T, Legac E. Case Report: Co-infection with SARS-CoV-2 and influenza H1N1 in a patient with acute respiratory distress syndrome and a pulmonary sarcoidosis. F1000Res 2022; 9:1482. [PMID: 35528205 PMCID: PMC9065929 DOI: 10.12688/f1000research.26924.2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 04/12/2022] [Indexed: 12/12/2022] Open
Abstract
Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and has been a global public health concern. We report coinfection of SARS-CoV-2 and 2009 H1N1 Influenza strain in a French patient with pneumonia leading to acute respiratory distress syndrome. The patient also had a medical history of pulmonary sarcoidosis with a restrictive ventilatory syndrome and obesity, which would be a supplementary risk to develop a poor outcomes. This case highlights the possible coinfection of two severe SARS-CoV-2 and influenza H1N1 viruses in comorbid patient, which presents a higher risk to extend the care duration. The overlapping clinical features of the two respiratory syndromes is a challenge, and awareness is required to recommend an early differential diagnosis and it’s necessary to adopt the vigilant preventive measures and therapeutic strategies to prevent a deleterious impacts in patients with comorbid factors.
Collapse
Affiliation(s)
- Lekbir Baala
- Pole de Biopathologie , CS 86709, 45067 Orléans CEDEX , France, Centre Hospitalier Régional d’Orléans, 14 Avenu de l’Hôpital, Orléans, France
- UMR7355 INEM Immunologie et Neurogénétique Expérimentales & Moléculaires, CNRS & Université d'Orléans, 3B rue de la Ferollerie, Orléans CEDEX 2, 45071, France
| | - Dalila Benzekri-Lefevre
- Service de Médecine Intensive Réanimation, Pole Métiers de l’Urgence, Centre Hospitalier Régional d’Orléans, 14 Avenu de l’Hôpital, CS 86709, Orélans, 45067, France
| | - Laurent Bret
- Pole de Biopathologie , CS 86709, 45067 Orléans CEDEX , France, Centre Hospitalier Régional d’Orléans, 14 Avenu de l’Hôpital, Orléans, France
| | - Toufik Kamel
- Service de Médecine Intensive Réanimation, Pole Métiers de l’Urgence, Centre Hospitalier Régional d’Orléans, 14 Avenu de l’Hôpital, CS 86709, Orélans, 45067, France
| | - Clémence Guillaume
- Pole de Biopathologie , CS 86709, 45067 Orléans CEDEX , France, Centre Hospitalier Régional d’Orléans, 14 Avenu de l’Hôpital, Orléans, France
| | - Laura Courtellemont
- Pole de Biopathologie , CS 86709, 45067 Orléans CEDEX , France, Centre Hospitalier Régional d’Orléans, 14 Avenu de l’Hôpital, Orléans, France
| | - Abdelkrim El Khalil
- Service de Pneumologie, Centre Hospitalier Régional d’Orléans, Orléans, 45067, France
| | - Thomas Guery
- Pole de Biopathologie , CS 86709, 45067 Orléans CEDEX , France, Centre Hospitalier Régional d’Orléans, 14 Avenu de l’Hôpital, Orléans, France
| | - Sophie Iquel
- Pole de Biopathologie , CS 86709, 45067 Orléans CEDEX , France, Centre Hospitalier Régional d’Orléans, 14 Avenu de l’Hôpital, Orléans, France
| | - Olivier Perche
- Pole de Biopathologie , CS 86709, 45067 Orléans CEDEX , France, Centre Hospitalier Régional d’Orléans, 14 Avenu de l’Hôpital, Orléans, France
- UMR7355 INEM Immunologie et Neurogénétique Expérimentales & Moléculaires, CNRS & Université d'Orléans, 3B rue de la Ferollerie, Orléans CEDEX 2, 45071, France
| | - Khalid Khadre
- Service de Radiologie, Centre Hospitalier Régional d’Orléans, Orléans, 45067, France
| | - Thomas Brungs
- Pole de Biopathologie , CS 86709, 45067 Orléans CEDEX , France, Centre Hospitalier Régional d’Orléans, 14 Avenu de l’Hôpital, Orléans, France
| | - Julien Decker
- Pole de Biopathologie , CS 86709, 45067 Orléans CEDEX , France, Centre Hospitalier Régional d’Orléans, 14 Avenu de l’Hôpital, Orléans, France
| | - Thomas Francia
- Pole de Biopathologie , CS 86709, 45067 Orléans CEDEX , France, Centre Hospitalier Régional d’Orléans, 14 Avenu de l’Hôpital, Orléans, France
| | - Julie Bois
- Pole de Biopathologie , CS 86709, 45067 Orléans CEDEX , France, Centre Hospitalier Régional d’Orléans, 14 Avenu de l’Hôpital, Orléans, France
| | - Benoit Delamare
- Pole de Biopathologie , CS 86709, 45067 Orléans CEDEX , France, Centre Hospitalier Régional d’Orléans, 14 Avenu de l’Hôpital, Orléans, France
| | - Jérôme Guinard
- Pole de Biopathologie , CS 86709, 45067 Orléans CEDEX , France, Centre Hospitalier Régional d’Orléans, 14 Avenu de l’Hôpital, Orléans, France
| | - Laurence Got
- Pole de Biopathologie , CS 86709, 45067 Orléans CEDEX , France, Centre Hospitalier Régional d’Orléans, 14 Avenu de l’Hôpital, Orléans, France
| | - Sylvain Briault
- Pole de Biopathologie , CS 86709, 45067 Orléans CEDEX , France, Centre Hospitalier Régional d’Orléans, 14 Avenu de l’Hôpital, Orléans, France
- UMR7355 INEM Immunologie et Neurogénétique Expérimentales & Moléculaires, CNRS & Université d'Orléans, 3B rue de la Ferollerie, Orléans CEDEX 2, 45071, France
| | - Thierry Boulain
- Service de Médecine Intensive Réanimation, Pole Métiers de l’Urgence, Centre Hospitalier Régional d’Orléans, 14 Avenu de l’Hôpital, CS 86709, Orélans, 45067, France
| | - Eric Legac
- Pole de Biopathologie , CS 86709, 45067 Orléans CEDEX , France, Centre Hospitalier Régional d’Orléans, 14 Avenu de l’Hôpital, Orléans, France
| |
Collapse
|
5
|
Perche O, Lesne F, Patat A, Raab S, Twyman R, Ring RH, Briault S. Electroretinography and contrast sensitivity, complementary translational biomarkers of sensory deficits in the visual system of individuals with fragile X syndrome. J Neurodev Disord 2021; 13:45. [PMID: 34625026 PMCID: PMC8501595 DOI: 10.1186/s11689-021-09375-0] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/08/2021] [Accepted: 07/30/2021] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND Disturbances in sensory function are an important clinical feature of neurodevelopmental disorders such as fragile X syndrome (FXS). Evidence also directly connects sensory abnormalities with the clinical expression of behavioral impairments in individuals with FXS; thus, positioning sensory function as a potential clinical target for the development of new therapeutics. Using electroretinography (ERG) and contrast sensitivity (CS), we previously reported the presence of sensory deficits in the visual system of the Fmr1-/y genetic mouse model of FXS. The goals of the current study were two-folds: (1) to assess the feasibility of measuring ERG and CS as a biomarker of sensory deficits in individuals with FXS, and (2) to investigate whether the deficits revealed by ERG and CS in Fmr1-/y mice translate to humans with FXS. METHODS Both ERG and CS were measured in a cohort of male individuals with FXS (n = 20, 18-45 years) and age-matched healthy controls (n = 20, 18-45 years). Under light-adapted conditions, and using both single flash and flicker (repeated train of flashes) stimulation protocols, retinal function was recorded from individual subjects using a portable, handheld, full-field flash ERG device (RETeval®, LKC Technologies Inc., Gaithersburg, MD, USA). CS was assessed in each subject using the LEA SYMBOLS® low-contrast test (Good-Lite, Elgin, IL, USA). RESULTS Data recording was successfully completed for ERG and assessment of CS in most individuals from both cohorts demonstrating the feasibility of these methods for use in the FXS population. Similar to previously reported findings from the Fmr1-/y genetic mouse model, individuals with FXS were found to exhibit reduced b-wave and flicker amplitude in ERG and an impaired ability to discriminate contrasts compared to healthy controls. CONCLUSIONS This study demonstrates the feasibility of using ERG and CS for assessing visual deficits in FXS and establishes the translational validity of the Fmr1-/y mice phenotype to individuals with FXS. By including electrophysiological and functional readouts, the results of this study suggest the utility of both ERG and CS (ERG-CS) as complementary translational biomarkers for characterizing sensory abnormalities found in FXS, with potential applications to the clinical development of novel therapeutics that target sensory function abnormalities to treat core symptomatology in FXS. TRIAL REGISTRATION ID-RCB number 2019-A01015-52 registered on the 17 May 2019.
Collapse
Affiliation(s)
- Olivier Perche
- Genetic Department, Centre Hospitalier Régional d'Orléans, Orléans, France
- UMR7355, Centre National de la Recherche Scientifique (CNRS), Orléans, France
- Experimental and Molecular Immunology and Neurogenetics, University of Orléans, Orléans, France
- Kaerus Bioscience Ltd., London, EC1Y 4YX, UK
| | | | - Alain Patat
- Kaerus Bioscience Ltd., London, EC1Y 4YX, UK
| | | | | | - Robert H Ring
- Kaerus Bioscience Ltd., London, EC1Y 4YX, UK
- Department of Pharmacology and Physiology, Drexel University College of Medicine, Philadelphia, PA, USA
| | - Sylvain Briault
- Genetic Department, Centre Hospitalier Régional d'Orléans, Orléans, France.
- UMR7355, Centre National de la Recherche Scientifique (CNRS), Orléans, France.
- Experimental and Molecular Immunology and Neurogenetics, University of Orléans, Orléans, France.
- Kaerus Bioscience Ltd., London, EC1Y 4YX, UK.
| |
Collapse
|
6
|
Rontani P, Perche O, Greetham L, Jullien N, Gepner B, Féron F, Nivet E, Erard-Garcia M. Impaired expression of the COSMOC/MOCOS gene unit in ASD patient stem cells. Mol Psychiatry 2021; 26:1606-1618. [PMID: 32327736 PMCID: PMC8159765 DOI: 10.1038/s41380-020-0728-2] [Citation(s) in RCA: 13] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/13/2019] [Revised: 03/17/2020] [Accepted: 04/03/2020] [Indexed: 12/16/2022]
Abstract
Autism spectrum disorders (ASD) are complex neurodevelopmental disorders with a very large number of risk loci detected in the genome. However, at best, each of them explains rare cases, the majority being idiopathic. Genomic data on ASD derive mostly from post-mortem brain analyses or cell lines derived from blood or patient-specific induced pluripotent stem cells (iPSCS). Therefore, the transcriptional and regulatory architecture of the nervous system, particularly during early developmental periods, remains highly incomplete. To access the critical disturbances that may have occurred during pregnancy or early childhood, we recently isolated stem cells from the nasal cavity of anesthetized patients diagnosed for ASD and compared them to stem cells from gender-matched control individuals without neuropsychiatric disorders. This allowed us to discover MOCOS, a non-mutated molybdenum cofactor sulfurase-coding gene that was under-expressed in the stem cells of most ASD patients of our cohort, disturbing redox homeostasis and synaptogenesis. We now report that a divergent transcription upstream of MOCOS generates an antisense long noncoding RNA, to which we coined the name COSMOC. Surprisingly, COSMOC is strongly under-expressed in all ASD patients of our cohort with the exception of a patient affected by Asperger syndrome. Knockdown studies indicate that loss of COSMOC reduces MOCOS expression, destabilizes lipid and energy metabolisms of stem cells, but also affects neuronal maturation and splicing of synaptic genes. Impaired expression of the COSMOC/MOCOS bidirectional unit might shed new lights on the origins of ASD that could be of importance for future translational studies.
Collapse
Affiliation(s)
- Pauline Rontani
- grid.5399.60000 0001 2176 4817Aix Marseille University, CNRS, INP, UMR 7051 Marseille, France
| | - Olivier Perche
- grid.112485.b0000 0001 0217 6921Orléans University, CNRS, INEM, UMR 7355 Orleans, France ,Department of Genetics, Regional Hospital, Orleans, France
| | - Louise Greetham
- grid.5399.60000 0001 2176 4817Aix Marseille University, CNRS, INP, UMR 7051 Marseille, France
| | - Nicolas Jullien
- grid.5399.60000 0001 2176 4817Aix Marseille University, CNRS, INP, UMR 7051 Marseille, France
| | - Bruno Gepner
- grid.5399.60000 0001 2176 4817Aix Marseille University, CNRS, INP, UMR 7051 Marseille, France
| | - François Féron
- grid.5399.60000 0001 2176 4817Aix Marseille University, CNRS, INP, UMR 7051 Marseille, France
| | - Emmanuel Nivet
- grid.5399.60000 0001 2176 4817Aix Marseille University, CNRS, INP, UMR 7051 Marseille, France
| | - Madeleine Erard-Garcia
- Aix Marseille University, CNRS, INP, UMR 7051, Marseille, France. .,Orléans University, CNRS, INEM, UMR 7355, Orleans, France.
| |
Collapse
|
7
|
Felgerolle C, Hébert B, Ardourel M, Meyer-Dilhet G, Menuet A, Pinto-Morais K, Bizot JC, Pichon J, Briault S, Perche O. Visual Behavior Impairments as an Aberrant Sensory Processing in the Mouse Model of Fragile X Syndrome. Front Behav Neurosci 2019; 13:228. [PMID: 31680892 PMCID: PMC6797836 DOI: 10.3389/fnbeh.2019.00228] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/13/2019] [Accepted: 09/12/2019] [Indexed: 12/02/2022] Open
Abstract
Fragile X Syndrome (FXS), the most common inherited form of human intellectual disability (ID) associated with autistic-like behaviors, is characterized by dys-sensitivity to sensory stimuli, especially vision. In the absence of Fragile Mental Retardation Protein (FMRP), both retinal and cerebral structures of the visual pathway are impaired, suggesting that perception and integration of visual stimuli are altered. However, behavioral consequences of these defects remain unknown. In this study, we used male Fmr1−/y mice to further define visual disturbances from a behavioral perspective by focusing on three traits characterizing visual modality: perception of depth, contrasts and movements. We performed specific tests (Optomotor Drum, Visual Cliff) to evaluate these visual modalities, their evolution from youth to adulthood, and to assess their involvement in a cognitive task. We show that Fmr1−/y mice exhibit alteration in their visual skills, displaying impaired perspective perception, a drop in their ability to understand a moving contrasted pattern, and a defect in contrasts discrimination. Interestingly, Fmr1−/y phenotypes remain stable over time from adolescence to late adulthood. Besides, we report that color and shape are meaningful for the achievement of a cognitive test involving object recognition. Altogether, these results underline the significance of visual behavior alterations in FXS conditions and relevance of assessing visual skills in neuropsychiatric models before performing behavioral tasks, such as cognitive assessments, that involve visual discrimination.
Collapse
Affiliation(s)
- Chloé Felgerolle
- UMR7355, CNRS, Orléans, France.,Experimental and Molecular Immunology and Neurogenetics, University of Orléans, Orléans, France
| | - Betty Hébert
- UMR7355, CNRS, Orléans, France.,Experimental and Molecular Immunology and Neurogenetics, University of Orléans, Orléans, France
| | - Maryvonne Ardourel
- UMR7355, CNRS, Orléans, France.,Experimental and Molecular Immunology and Neurogenetics, University of Orléans, Orléans, France
| | - Géraldine Meyer-Dilhet
- UMR7355, CNRS, Orléans, France.,Experimental and Molecular Immunology and Neurogenetics, University of Orléans, Orléans, France
| | - Arnaud Menuet
- UMR7355, CNRS, Orléans, France.,Experimental and Molecular Immunology and Neurogenetics, University of Orléans, Orléans, France
| | - Kimberley Pinto-Morais
- UMR7355, CNRS, Orléans, France.,Experimental and Molecular Immunology and Neurogenetics, University of Orléans, Orléans, France
| | | | - Jacques Pichon
- UMR7355, CNRS, Orléans, France.,Experimental and Molecular Immunology and Neurogenetics, University of Orléans, Orléans, France
| | - Sylvain Briault
- UMR7355, CNRS, Orléans, France.,Experimental and Molecular Immunology and Neurogenetics, University of Orléans, Orléans, France.,Department of Genetics, Regional Hospital, Orléans, France
| | - Olivier Perche
- UMR7355, CNRS, Orléans, France.,Experimental and Molecular Immunology and Neurogenetics, University of Orléans, Orléans, France.,Department of Genetics, Regional Hospital, Orléans, France
| |
Collapse
|
8
|
Laviolle B, Perche O, Gueyffier F, Bégué É, Bilbault P, Espérou H, Gaillard-Bigot F, Grenet G, Guérin JF, Guillot C, Longeray PH, Morere J, Perrier L, Sanlaville D, Thevenon J, Varoqueaux N. Apport de la génomique dans la médecine de demain, applications cliniques et enjeux. Therapie 2019; 74:1-8. [DOI: 10.1016/j.therap.2018.11.011] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2018] [Accepted: 11/13/2018] [Indexed: 11/24/2022]
|
9
|
Laviolle B, Denèfle P, Gueyffier F, Bégué É, Bilbault P, Espérou H, Gaillard-Bigot F, Grenet G, Guérin JF, Guillot C, Longeray PH, Morere J, Perche O, Perrier L, Sanlaville D, Thevenon J, Varoqueaux N. The contribution of genomics in the medicine of tomorrow, clinical applications and issues. Therapie 2019; 74:9-15. [DOI: 10.1016/j.therap.2018.11.012] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2018] [Accepted: 11/13/2018] [Indexed: 10/27/2022]
|
10
|
Perche O, Felgerolle C, Ardourel M, Bazinet A, Pâris A, Rossignol R, Meyer-Dilhet G, Mausset-Bonnefont AL, Hébert B, Laurenceau D, Montécot-Dubourg C, Menuet A, Bizot JC, Pichon J, Ranchon-Cole I, Briault S. Early Retinal Defects in Fmr1-/y Mice: Toward a Critical Role of Visual Dys-Sensitivity in the Fragile X Syndrome Phenotype? Front Cell Neurosci 2018; 12:96. [PMID: 29681800 PMCID: PMC5897671 DOI: 10.3389/fncel.2018.00096] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/24/2017] [Accepted: 03/22/2018] [Indexed: 12/29/2022] Open
Abstract
Fragile X Syndrome (FXS) is caused by a deficiency in Fragile X Mental Retardation Protein (FMRP) leading to global sensorial abnormalities, among which visual defects represent a critical part. These visual defects are associated with cerebral neuron immaturity especially in the primary visual cortex. However, we recently demonstrated that retinas of adult Fmr1−/y mice, the FXS murine model, present molecular, cellular and functional alterations. However, no data are currently available on the evolution pattern of such defects. As retinal stimulation through Eye Opening (EO) is a crucial signal for the cerebral visual system maturation, we questioned the precocity of molecular and functional retinal phenotype. To answer this question, we studied the retinal molecular phenotype of Fmr1−/y mice before EO until adult age and the consequences of the retinal loss of Fmrp on retinal function in young and adult mice. We showed that retinal molecular defects are present before EO and remain stable at adult age, leading to electrophysiological impairments without any underlying structural changes. We underlined that loss of Fmrp leads to a wide range of defects in the retina, settled even before EO. Our work demonstrates a critical role of the sensorial dysfunction in the Fmr1−/y mice overall phenotype, and provides evidence that altered peripheral perception is a component of the sensory processing defect in FXS conditions.
Collapse
Affiliation(s)
- Olivier Perche
- Genetic Department, Centre Hospitalier Régional d'Orléans, Orléans, France.,UMR7355, Immunologie et Neurogénétique Expérimentales et Moléculaires (INEM), Centre National de la Recherche Scientifique, Orléans, France.,Experimental and Molecular Immunology and Neurogenetics, University of Orléans, Orléans, France
| | - Chloé Felgerolle
- UMR7355, Immunologie et Neurogénétique Expérimentales et Moléculaires (INEM), Centre National de la Recherche Scientifique, Orléans, France.,Experimental and Molecular Immunology and Neurogenetics, University of Orléans, Orléans, France
| | - Maryvonne Ardourel
- UMR7355, Immunologie et Neurogénétique Expérimentales et Moléculaires (INEM), Centre National de la Recherche Scientifique, Orléans, France.,Experimental and Molecular Immunology and Neurogenetics, University of Orléans, Orléans, France
| | - Audrey Bazinet
- UMR7355, Immunologie et Neurogénétique Expérimentales et Moléculaires (INEM), Centre National de la Recherche Scientifique, Orléans, France.,Experimental and Molecular Immunology and Neurogenetics, University of Orléans, Orléans, France
| | - Arnaud Pâris
- UMR7355, Immunologie et Neurogénétique Expérimentales et Moléculaires (INEM), Centre National de la Recherche Scientifique, Orléans, France.,Experimental and Molecular Immunology and Neurogenetics, University of Orléans, Orléans, France
| | - Rafaëlle Rossignol
- UMR7355, Immunologie et Neurogénétique Expérimentales et Moléculaires (INEM), Centre National de la Recherche Scientifique, Orléans, France.,Experimental and Molecular Immunology and Neurogenetics, University of Orléans, Orléans, France
| | - Géraldine Meyer-Dilhet
- UMR7355, Immunologie et Neurogénétique Expérimentales et Moléculaires (INEM), Centre National de la Recherche Scientifique, Orléans, France.,Experimental and Molecular Immunology and Neurogenetics, University of Orléans, Orléans, France
| | | | - Betty Hébert
- UMR7355, Immunologie et Neurogénétique Expérimentales et Moléculaires (INEM), Centre National de la Recherche Scientifique, Orléans, France.,Experimental and Molecular Immunology and Neurogenetics, University of Orléans, Orléans, France
| | - David Laurenceau
- Genetic Department, Centre Hospitalier Régional d'Orléans, Orléans, France
| | - Céline Montécot-Dubourg
- UMR7355, Immunologie et Neurogénétique Expérimentales et Moléculaires (INEM), Centre National de la Recherche Scientifique, Orléans, France.,Experimental and Molecular Immunology and Neurogenetics, University of Orléans, Orléans, France
| | - Arnaud Menuet
- UMR7355, Immunologie et Neurogénétique Expérimentales et Moléculaires (INEM), Centre National de la Recherche Scientifique, Orléans, France.,Experimental and Molecular Immunology and Neurogenetics, University of Orléans, Orléans, France
| | | | - Jacques Pichon
- UMR7355, Immunologie et Neurogénétique Expérimentales et Moléculaires (INEM), Centre National de la Recherche Scientifique, Orléans, France.,Experimental and Molecular Immunology and Neurogenetics, University of Orléans, Orléans, France
| | - Isabelle Ranchon-Cole
- Laboratory of Sensorial Biophysical, INSERM UMR1107 Equipe Biophysique Neurosensorielle, University of Clermont 1, Clermont-Ferrand, France
| | - Sylvain Briault
- Genetic Department, Centre Hospitalier Régional d'Orléans, Orléans, France.,UMR7355, Immunologie et Neurogénétique Expérimentales et Moléculaires (INEM), Centre National de la Recherche Scientifique, Orléans, France.,Experimental and Molecular Immunology and Neurogenetics, University of Orléans, Orléans, France
| |
Collapse
|
11
|
Laugeray A, Herzine A, Perche O, Richard O, Montecot-Dubourg C, Menuet A, Mazaud-Guittot S, Lesné L, Jegou B, Mortaud S. In utero and lactational exposure to low-doses of the pyrethroid insecticide cypermethrin leads to neurodevelopmental defects in male mice-An ethological and transcriptomic study. PLoS One 2017; 12:e0184475. [PMID: 29020013 PMCID: PMC5636066 DOI: 10.1371/journal.pone.0184475] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2017] [Accepted: 08/19/2017] [Indexed: 01/03/2023] Open
Abstract
Accumulating evidence suggests that developmental exposure to environmental chemicals may modify the course of brain development, ultimately leading to neuropsychiatric / neurodegenerative disorders later in life. In the present study, we assessed the impact of one of the most frequently used pesticides in both residential and agricultural applications − the synthetic pyrethroid cypermethrin (CYP) − on developmental neurotoxicity (DNT). Female mice were perinatally exposed to low doses of CYP (5 and 20 mg/kg body weight) from gestation to postnatal day 15. Behavioral analyses were performed during the offspring’s early life and during adulthood. Postnatal analyses revealed that perinatal exposure to CYP disturbed motor development without modifying sensory and communicative skills. We found that later in life, CYP-exposed offspring expressed maladaptive behaviors in response to highly challenging tasks and abnormal sociability. Transcriptomic analyses performed in the offspring’s brain at the end of the exposure, highlighted mitochondrial dysfunction as a relevant pathomechanism underlying CYP-induced DNT. Interestingly, several genes involved in proteostasis maintenance were also shown to be dysregulated suggesting that alterations in biogenesis, folding, trafficking and degradation of proteins may significantly contribute to CYP-related DNT. From a regulatory perspective, this study highlights that behavioral and transcriptomic analyses are complementary tools providing useful direction for better DNT characterization, and as such, should be used together more systematically.
Collapse
Affiliation(s)
- Anthony Laugeray
- Immunologie et Neurogénétique Expérimentales et Moléculaires – UMR7355 CNRS – Orléans, France
- * E-mail: (AL); (SM)
| | - Ameziane Herzine
- Immunologie et Neurogénétique Expérimentales et Moléculaires – UMR7355 CNRS – Orléans, France
| | - Olivier Perche
- Immunologie et Neurogénétique Expérimentales et Moléculaires – UMR7355 CNRS – Orléans, France
- Département de génétique, Center Hospitalier Régional, Orléans, France
| | - Olivier Richard
- Immunologie et Neurogénétique Expérimentales et Moléculaires – UMR7355 CNRS – Orléans, France
| | - Céline Montecot-Dubourg
- Immunologie et Neurogénétique Expérimentales et Moléculaires – UMR7355 CNRS – Orléans, France
| | - Arnaud Menuet
- Immunologie et Neurogénétique Expérimentales et Moléculaires – UMR7355 CNRS – Orléans, France
| | | | | | - Bernard Jegou
- IRSET INSERM U 1085, Université de Rennes I, Rennes, France
| | - Stéphane Mortaud
- Immunologie et Neurogénétique Expérimentales et Moléculaires – UMR7355 CNRS – Orléans, France
- * E-mail: (AL); (SM)
| |
Collapse
|
12
|
Herzine A, Laugeray A, Feat J, Menuet A, Quesniaux V, Richard O, Pichon J, Montécot-Dubourg C, Perche O, Mortaud S. Perinatal Exposure to Glufosinate Ammonium Herbicide Impairs Neurogenesis and Neuroblast Migration through Cytoskeleton Destabilization. Front Cell Neurosci 2016; 10:191. [PMID: 27555806 PMCID: PMC4977287 DOI: 10.3389/fncel.2016.00191] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2016] [Accepted: 07/19/2016] [Indexed: 11/13/2022] Open
Abstract
Neurogenesis, a process of generating functional neurons from neural precursors, occurs throughout life in restricted brain regions such as the subventricular zone (SVZ). During this process, newly generated neurons migrate along the rostral migratory stream to the olfactory bulb to replace granule cells and periglomerular neurons. This neuronal migration is pivotal not only for neuronal plasticity but also for adapted olfactory based behaviors. Perturbation of this highly controlled system by exogenous chemicals has been associated with neurodevelopmental disorders. We reported recently that perinatal exposure to low dose herbicide glufosinate ammonium (GLA), leads to long lasting behavioral defects reminiscent of Autism Spectrum Disorder-like phenotype in the offspring (Laugeray et al., 2014). Herein, we demonstrate that perinatal exposure to low dose GLA induces alterations in neuroblast proliferation within the SVZ and abnormal migration from the SVZ to the olfactory bulbs. These disturbances are not only concomitant to changes in cell morphology, proliferation and apoptosis, but are also associated with transcriptomic changes. Therefore, we demonstrate for the first time that perinatal exposure to low dose GLA alters SVZ neurogenesis. Jointly with our previous work, the present results provide new evidence on the link between molecular and cellular consequences of early life exposure to the herbicide GLA and the onset of ASD-like phenotype later in life.
Collapse
Affiliation(s)
- Ameziane Herzine
- UMR7355, Centre National de la Recherche ScientifiqueOrleans, France; Immunologie et Neurogénétique Expérimentales et Moléculaires, Experimental and Molecular Immunology and Neurogenetics, University of OrleansOrleans, France
| | - Anthony Laugeray
- UMR7355, Centre National de la Recherche ScientifiqueOrleans, France; Immunologie et Neurogénétique Expérimentales et Moléculaires, Experimental and Molecular Immunology and Neurogenetics, University of OrleansOrleans, France
| | - Justyne Feat
- UMR7355, Centre National de la Recherche ScientifiqueOrleans, France; Immunologie et Neurogénétique Expérimentales et Moléculaires, Experimental and Molecular Immunology and Neurogenetics, University of OrleansOrleans, France
| | - Arnaud Menuet
- UMR7355, Centre National de la Recherche ScientifiqueOrleans, France; Immunologie et Neurogénétique Expérimentales et Moléculaires, Experimental and Molecular Immunology and Neurogenetics, University of OrleansOrleans, France
| | - Valérie Quesniaux
- UMR7355, Centre National de la Recherche ScientifiqueOrleans, France; Immunologie et Neurogénétique Expérimentales et Moléculaires, Experimental and Molecular Immunology and Neurogenetics, University of OrleansOrleans, France
| | - Olivier Richard
- UMR7355, Centre National de la Recherche ScientifiqueOrleans, France; Immunologie et Neurogénétique Expérimentales et Moléculaires, Experimental and Molecular Immunology and Neurogenetics, University of OrleansOrleans, France
| | - Jacques Pichon
- UMR7355, Centre National de la Recherche ScientifiqueOrleans, France; Immunologie et Neurogénétique Expérimentales et Moléculaires, Experimental and Molecular Immunology and Neurogenetics, University of OrleansOrleans, France
| | - Céline Montécot-Dubourg
- UMR7355, Centre National de la Recherche ScientifiqueOrleans, France; Immunologie et Neurogénétique Expérimentales et Moléculaires, Experimental and Molecular Immunology and Neurogenetics, University of OrleansOrleans, France
| | - Olivier Perche
- UMR7355, Centre National de la Recherche ScientifiqueOrleans, France; Immunologie et Neurogénétique Expérimentales et Moléculaires, Experimental and Molecular Immunology and Neurogenetics, University of OrleansOrleans, France; Genetics Department, Regional HospitalOrleans, France
| | - Stéphane Mortaud
- UMR7355, Centre National de la Recherche ScientifiqueOrleans, France; Immunologie et Neurogénétique Expérimentales et Moléculaires, Experimental and Molecular Immunology and Neurogenetics, University of OrleansOrleans, France
| |
Collapse
|
13
|
Wurcel V, Perche O, Lesteven D, Williams DA, Schäfer B, Hopley C, Jungwirth R, Postulka A, Pasmans R, Hermansson LL, Ott M, Glorioso V. The Value of Companion Diagnostics: Overcoming Access Barriers to Transform Personalised Health Care into an Affordable Reality in Europe. Public Health Genomics 2016; 19:137-43. [PMID: 27237134 DOI: 10.1159/000446531] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
Abstract
Personalised health care is an evolution, moving away from a disease-focused model of care, translating scientific and technological advances into benefits for patients, and placing them at the centre of the patients' health and care. Companion diagnostics emerge as a very specific and special group of in vitro diagnostics among the different technologies shaping the personalised health care spectrum. Companion diagnostics provide highly valuable information, allowing patients, health practitioners and payers to decide with a higher level of certainty on the potential benefits of a treatment or care pathway. Decreasing uncertainty may result in a more efficient selection of treatments and care, targeted at subpopulations that are most likely to benefit. Companion diagnostics account for a minimal portion of the already small expenditure on in vitro diagnostics (far less than 1% of total health care expenditure), and yet they provide the means to limit inefficient use of health care resources while optimising patient outcomes. It is clear that equal access to personalised health care is still an issue across the EU. One of the most common perceived barriers is affordability. The investment in companion diagnostics can provide long-term value for patients and health care systems, shifting resources to areas of need. Health systems do not fully recognise yet the value that companion diagnostics bring to make personalised health care more affordable across the EU. This inhibits patient access to personalised treatments and care, preventing improved outcomes. In many countries, market access frameworks for diagnostic tests are fragmented and not aligned with specific funding and reimbursement mechanisms, discouraging the use of these tests. Emerging evidence shows that patients are missing out on the appropriate tests and treatments while a reduction in the inefficient use of health care resources is not realised. This article outlines some of these market access barriers for companion diagnostics in the EU, including reimbursement challenges specific to some member states (Germany, the UK, and France). Furthermore, proposals addressing barriers and increasing timely patient access to companion diagnostics in the EU are presented.
Collapse
Affiliation(s)
- Victoria Wurcel
- EDMA, The European Diagnostic Manufacturers Association, Member of MedTech Europe, Brussels, Belgium
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Laudier B, Epiais T, Pâris A, Menuet A, Briault S, Ozsancak C, Perche O. Molecular and clinical analyses with neuropsychological assessment of a case of del(10)(q26.2qter) without intellectual disability: Genomic and transcriptomic combined approach and review of the literature. Am J Med Genet A 2016; 170:1806-12. [PMID: 27113058 DOI: 10.1002/ajmg.a.37677] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/16/2014] [Accepted: 04/03/2016] [Indexed: 11/10/2022]
Abstract
Terminal deletion of the long arm of the chromosome 10 is a rare but well known abnormality, with a large phenotypic variability. Very few data are available about subtelomeric deletion 10q26 patients without intellectual disability. Herein, we report the case of a young adult with a classical 10q26.2qter deletion. She exhibited mainly short stature at birth and in childhood/adulthood without intellectual disability or behavioral problems. After clinical and neuropsychological assessments, we performed genomic array and transcriptomic analysis and compared our results to the data available in the literature. The patient presents a 6.525 Mb heterozygous 10q26.2qter deletion, encompassed 48 genes. Among those genes, DOCK1, C10orf90, and CALY previously described as potential candidate genes for intellectual disability, were partially or completed deleted. Interestingly, they were not deregulated as demonstrated by transcriptomic analysis. This allowed us to suggest that the mechanism involved in the deletion 10qter phenotype is much more complex that only the haploinsufficiency of DOCK1 or other genes encompassed in the deletion. Genomic and transcriptomic combined approach has to be considered to understand this pathogenesis. © 2016 Wiley Periodicals, Inc.
Collapse
Affiliation(s)
- Béatrice Laudier
- UMR7355, CNRS, Orleans, France.,Experimental and Molecular Immunology and Neurogenetics, University of Orleans, Orleans, France.,Department of Genetics, Regional Hospital, Orleans, France
| | | | - Arnaud Pâris
- UMR7355, CNRS, Orleans, France.,Experimental and Molecular Immunology and Neurogenetics, University of Orleans, Orleans, France
| | - Arnaud Menuet
- UMR7355, CNRS, Orleans, France.,Experimental and Molecular Immunology and Neurogenetics, University of Orleans, Orleans, France
| | - Sylvain Briault
- UMR7355, CNRS, Orleans, France.,Experimental and Molecular Immunology and Neurogenetics, University of Orleans, Orleans, France.,Department of Genetics, Regional Hospital, Orleans, France
| | - Canan Ozsancak
- Department of Neurology, Regional Hospital, Orleans, France
| | - Olivier Perche
- UMR7355, CNRS, Orleans, France.,Experimental and Molecular Immunology and Neurogenetics, University of Orleans, Orleans, France.,Department of Genetics, Regional Hospital, Orleans, France
| |
Collapse
|
15
|
Guimarães-Souza EM, Perche O, Morgans CW, Duvoisin RM, Calaza KC. Fragile X Mental Retardation Protein expression in the retina is regulated by light. Exp Eye Res 2015; 146:72-82. [PMID: 26719241 DOI: 10.1016/j.exer.2015.11.025] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2015] [Revised: 11/27/2015] [Accepted: 11/30/2015] [Indexed: 01/29/2023]
Abstract
Fragile X Mental Retardation Protein (FMRP) is a RNA-binding protein that modulates protein synthesis at the synapse and its function is regulated by glutamate. The retina is the first structure that participates in vision, and uses glutamate to transduce electromagnetic signals from light to electrochemical signals to neurons. FMRP has been previously detected in the retina, but its localization has not been studied yet. In this work, our objectives were to describe the localization of FMRP in the retina, to determine whether different exposure to dark or light stimulus alters FMRP expression in the retina, and to compare the pattern in two different species, the mouse and chick. We found that both FMRP mRNA and protein are expressed in the retina. By immunohistochemistry analysis we found that both mouse and chick present similar FMRP expression localized mainly in both plexiform layers and the inner retina. It was also observed that FMRP is down-regulated by 24 h dark adaptation compared to its expression in the retina of animals that were exposed to light for 1 h after 24 h in the dark. We conclude that FMRP is likely to participate in retinal physiology, since its expression changes with light exposure. In addition, the expression pattern and regulation by light of FMRP seems well conserved since it was similar in both mouse and chick.
Collapse
Affiliation(s)
- E M Guimarães-Souza
- Neurosciences Program, Biology Institute, Federal Fluminense University, Niterói, Rio de Janeiro, Brazil
| | - O Perche
- Genetic Department, Regional Hospital, Orléans, France; UMR7355, CNRS, Orléans, France; Experimental and Molecular Immunology and Neurogenetics, CNRS, University of Orléans, Orléans, France
| | - C W Morgans
- Department of Physiology & Pharmacology, Oregon Health &Science University, Portland, OR, USA
| | - R M Duvoisin
- Department of Physiology & Pharmacology, Oregon Health &Science University, Portland, OR, USA
| | - K C Calaza
- Neurosciences Program, Biology Institute, Federal Fluminense University, Niterói, Rio de Janeiro, Brazil.
| |
Collapse
|
16
|
Marquet P, Longeray PH, Barlesi F, Ameye V, Augé P, Cazeneuve B, Chatelut E, Diaz I, Diviné M, Froguel P, Goni S, Gueyffier F, Hoog-Labouret N, Mourah S, Morin-Surroca M, Perche O, Perin-Dureau F, Pigeon M, Tisseau A, Verstuyft C. Translational research: precision medicine, personalized medicine, targeted therapies: marketing or science? Therapie 2015; 70:1-19. [PMID: 25679189 DOI: 10.2515/therapie/2014231] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2014] [Accepted: 12/18/2014] [Indexed: 12/28/2022]
Abstract
Personalized medicine is based on: 1) improved clinical or non-clinical methods (including biomarkers) for a more discriminating and precise diagnosis of diseases; 2) targeted therapies of the choice or the best drug for each patient among those available; 3) dose adjustment methods to optimize the benefit-risk ratio of the drugs chosen; 4) biomarkers of efficacy, toxicity, treatment discontinuation, relapse, etc. Unfortunately, it is still too often a theoretical concept because of the lack of convenient diagnostic methods or treatments, particularly of drugs corresponding to each subtype of pathology, hence to each patient. Stratified medicine is a component of personalized medicine employing biomarkers and companion diagnostics to target the patients likely to present the best benefit-risk balance for a given active compound. The concept of targeted therapy, mostly used in cancer treatment, relies on the existence of a defined molecular target, involved or not in the pathological process, and/or on the existence of a biomarker able to identify the target population, which should logically be small as compared to the population presenting the disease considered. Targeted therapies and biomarkers represent important stakes for the pharmaceutical industry, in terms of market access, of return on investment and of image among the prescribers. At the same time, they probably represent only the first generation of products resulting from the combination of clinical, pathophysiological and molecular research, i.e. of translational research.
Collapse
Affiliation(s)
- Pierre Marquet
- UMR 850 INSERM, CHU Limoges, Université de Limoges, Limoges, France
| | | | - Fabrice Barlesi
- Aix Marseille Université; Assistance Publique - Hôpitaux de Marseille, Service d'Oncologie Multidisciplinaire et Innovations Thérapeutiques, Marseille, France
| | | | | | | | | | | | | | | | - Philippe Froguel
- Imperial College, London, Royaume-Uni - Institut Pasteur, Lille, France
| | - Sylvia Goni
- Laboratoire Lundbeck SASIssy-les-MoulineauxFrance
| | | | | | - Samia Mourah
- Assistance publique - Hôpitaux de Paris, Paris, France - Université Paris 7, Paris, France - Inserm, Paris, France
| | | | | | | | | | | | - Céline Verstuyft
- Assistance publique - Hôpitaux de Paris, Paris, France - Faculté de Médecine Paris-Sud, Le Kremlin Bicêtre, France
| |
Collapse
|
17
|
Marquet P, Longeray PH, Barlesi F, Ameye V, Augé P, Cazeneuve B, Chatelut E, Diaz I, Diviné M, Froguel P, Goni S, Gueyffier F, Hoog-Labouret N, Mourah S, Morin-Surroca M, Perche O, Perin-Dureau F, Pigeon M, Tisseau A, Verstuyft C. Recherche translationnelle : médecine personnalisée, médecine de précision, thérapies ciblées : marketing ou science ? Therapie 2015; 70:1-10. [DOI: 10.2515/therapie/2014230] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2014] [Accepted: 12/18/2014] [Indexed: 11/20/2022]
|
18
|
Laugeray A, Herzine A, Perche O, Hébert B, Aguillon-Naury M, Richard O, Menuet A, Mazaud-Guittot S, Lesné L, Briault S, Jegou B, Pichon J, Montécot-Dubourg C, Mortaud S. Pre- and postnatal exposure to low dose glufosinate ammonium induces autism-like phenotypes in mice. Front Behav Neurosci 2014; 8:390. [PMID: 25477793 PMCID: PMC4238406 DOI: 10.3389/fnbeh.2014.00390] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/19/2014] [Accepted: 10/20/2014] [Indexed: 12/29/2022] Open
Abstract
Glufosinate ammonium (GLA) is one of the most widely used herbicides in agriculture. As is the case for most pesticides, potential adverse effects of GLA have not been studied from the perspective of developmental neurotoxicity. Early pesticides exposure may weaken the basic structure of the developing brain and cause permanent changes leading to a wide range of lifelong effects on health and/or behavior. Here, we addressed the developmental impact of GLA by exposing female mice to low dose GLA during both pre- and postnatal periods and analyzed potential developmental and behavioral changes of the offspring during infancy and adulthood. A neurobehavioral test battery revealed significant effects of GLA maternal exposure on early reflex development, pup communication, affiliative behaviors, and preference for social olfactory cues, but emotional reactivity and emotional memory remained unaltered. These behavioral alterations showed a striking resemblance to changes seen in animal models of Autistic Spectrum Disorders. At the brain level, GLA maternal exposure caused some increase in relative brain weight of the offspring. In addition, reduced expression of Pten and Peg3 – two genes implicated in autism-like deficits – was observed in the brain of GLA-exposed pups at postnatal day 15. Our work thus provides new data on the link between pre- and postnatal exposure to the herbicide GLA and the onset of autism-like symptoms later in life. It also raises fundamental concerns about the ability of current safety testing to assess risks of pesticide exposure during critical developmental periods.
Collapse
Affiliation(s)
- Anthony Laugeray
- Immunologie et Neurogénétique Expérimentales et Moléculaires - UMR7355 CNRS - 3b , Orléans , France
| | - Ameziane Herzine
- Immunologie et Neurogénétique Expérimentales et Moléculaires - UMR7355 CNRS - 3b , Orléans , France
| | - Olivier Perche
- Immunologie et Neurogénétique Expérimentales et Moléculaires - UMR7355 CNRS - 3b , Orléans , France ; Département de génétique, Centre Hospitalier Régional , Orléans , France
| | - Betty Hébert
- Immunologie et Neurogénétique Expérimentales et Moléculaires - UMR7355 CNRS - 3b , Orléans , France
| | | | - Olivier Richard
- Immunologie et Neurogénétique Expérimentales et Moléculaires - UMR7355 CNRS - 3b , Orléans , France ; Université d'Orléans , Orléans , France
| | - Arnaud Menuet
- Immunologie et Neurogénétique Expérimentales et Moléculaires - UMR7355 CNRS - 3b , Orléans , France ; Université d'Orléans , Orléans , France
| | | | - Laurianne Lesné
- IRSET INSERM U 1085, Université de Rennes I , Rennes , France
| | - Sylvain Briault
- Immunologie et Neurogénétique Expérimentales et Moléculaires - UMR7355 CNRS - 3b , Orléans , France ; Département de génétique, Centre Hospitalier Régional , Orléans , France
| | - Bernard Jegou
- IRSET INSERM U 1085, Université de Rennes I , Rennes , France
| | - Jacques Pichon
- Immunologie et Neurogénétique Expérimentales et Moléculaires - UMR7355 CNRS - 3b , Orléans , France ; Université d'Orléans , Orléans , France
| | - Céline Montécot-Dubourg
- Immunologie et Neurogénétique Expérimentales et Moléculaires - UMR7355 CNRS - 3b , Orléans , France ; Université d'Orléans , Orléans , France
| | - Stéphane Mortaud
- Immunologie et Neurogénétique Expérimentales et Moléculaires - UMR7355 CNRS - 3b , Orléans , France ; Université d'Orléans , Orléans , France
| |
Collapse
|
19
|
Laugeray A, Herzine A, Perche O, Richard O, Menuet A, Mazaud-Guittot S, Lesne L, Briault S, Jegou B, Pichon J, Montecot-Dubourg C, Mortaud S. Perinatal exposure to low dose glufosinate ammonium induces autism-like phenotypes in mice. Toxicol Lett 2014. [DOI: 10.1016/j.toxlet.2014.06.191] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
20
|
Rossignol R, Ranchon-Cole I, Pâris A, Herzine A, Perche A, Laurenceau D, Bertrand P, Cercy C, Pichon J, Mortaud S, Briault S, Menuet A, Perche O. Visual sensorial impairments in neurodevelopmental disorders: evidence for a retinal phenotype in Fragile X Syndrome. PLoS One 2014; 9:e105996. [PMID: 25153086 PMCID: PMC4143372 DOI: 10.1371/journal.pone.0105996] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/23/2014] [Accepted: 07/25/2014] [Indexed: 01/28/2023] Open
Abstract
Visual sensory impairments are common in Mental Deficiency (MD) and Autism Spectrum Disorder (ASD). These defects are linked to cerebral dysfunction in the visual cortical area characterized by the deregulation of axon growth/guidance and dendrite spine immaturity of neurons. However, visual perception had not been addressed, although the retina is part of the central nervous system with a common embryonic origin. Therefore, we investigated retinal perception, the first event of vision, in a murine model of MD with autistic features. We document that retinal function is altered in Fmr1 KO mice, a model of human Fragile X Syndrome. Indeed, In Fmr1 KO mice had a lower retinal function characterized by a decreased photoreceptors neuron response, due to a 40% decrease in Rhodopsin content and to Rod Outer Segment destabilization. In addition, we observed an alteration of the visual signal transmission between photoreceptors and the inner retina which could be attributed to deregulations of pre- and post- synaptic proteins resulting in retinal neurons synaptic destabilization and to retinal neurons immaturity. Thus, for the first time, we demonstrated that retinal perception is altered in a murine model of MD with autistic features and that there are strong similarities between cerebral and retinal cellular and molecular defects. Our results suggest that both visual perception and integration must be taken into account in assessing visual sensory impairments in MD and ASD.
Collapse
Affiliation(s)
- Rafaëlle Rossignol
- UMR7355, CNRS, Orléans, France
- Experimental and Molecular Immunology and Neurogenetics, University of Orléans, Orléans, France
| | - Isabelle Ranchon-Cole
- Laboratory of Sensorial Biophysical, University of Clermont 1, Clermont-Ferrand, France
| | - Arnaud Pâris
- UMR7355, CNRS, Orléans, France
- Experimental and Molecular Immunology and Neurogenetics, University of Orléans, Orléans, France
| | - Ameziane Herzine
- UMR7355, CNRS, Orléans, France
- Experimental and Molecular Immunology and Neurogenetics, University of Orléans, Orléans, France
| | - Astrid Perche
- Genetic Department, Regional Hospital, Orléans, France
| | | | - Pauline Bertrand
- Laboratory of Sensorial Biophysical, University of Clermont 1, Clermont-Ferrand, France
| | - Christine Cercy
- Laboratory of Sensorial Biophysical, University of Clermont 1, Clermont-Ferrand, France
| | - Jacques Pichon
- UMR7355, CNRS, Orléans, France
- Experimental and Molecular Immunology and Neurogenetics, University of Orléans, Orléans, France
| | - Stéphane Mortaud
- UMR7355, CNRS, Orléans, France
- Experimental and Molecular Immunology and Neurogenetics, University of Orléans, Orléans, France
| | - Sylvain Briault
- UMR7355, CNRS, Orléans, France
- Experimental and Molecular Immunology and Neurogenetics, University of Orléans, Orléans, France
- Genetic Department, Regional Hospital, Orléans, France
| | - Arnaud Menuet
- UMR7355, CNRS, Orléans, France
- Experimental and Molecular Immunology and Neurogenetics, University of Orléans, Orléans, France
| | - Olivier Perche
- UMR7355, CNRS, Orléans, France
- Experimental and Molecular Immunology and Neurogenetics, University of Orléans, Orléans, France
- Genetic Department, Regional Hospital, Orléans, France
- * E-mail:
| |
Collapse
|
21
|
Hébert B, Pietropaolo S, Même S, Laudier B, Laugeray A, Doisne N, Quartier A, Lefeuvre S, Got L, Cahard D, Laumonnier F, Crusio WE, Pichon J, Menuet A, Perche O, Briault S. Rescue of fragile X syndrome phenotypes in Fmr1 KO mice by a BKCa channel opener molecule. Orphanet J Rare Dis 2014; 9:124. [PMID: 25079250 PMCID: PMC4237919 DOI: 10.1186/s13023-014-0124-6] [Citation(s) in RCA: 70] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/10/2014] [Accepted: 07/21/2014] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND Fragile X Syndrome (FXS) is the most common form of inherited intellectual disability and is also associated with autism spectrum disorders. Previous studies implicated BKCa channels in the neuropathogenesis of FXS, but the main question was whether pharmacological BKCa stimulation would be able to rescue FXS neurobehavioral phenotypes. METHODS AND RESULTS We used a selective BKCa channel opener molecule (BMS-204352) to address this issue in Fmr1 KO mice, modeling the FXS pathophysiology. In vitro, acute BMS-204352 treatment (10 μM) restored the abnormal dendritic spine phenotype. In vivo, a single injection of BMS-204352 (2 mg/kg) rescued the hippocampal glutamate homeostasis and the behavioral phenotype. Indeed, disturbances in social recognition and interaction, non-social anxiety, and spatial memory were corrected by BMS-204352 in Fmr1 KO mice. CONCLUSION These results demonstrate that the BKCa channel is a new therapeutic target for FXS. We show that BMS-204352 rescues a broad spectrum of behavioral impairments (social, emotional and cognitive) in an animal model of FXS. This pharmacological molecule might open new ways for FXS therapy.
Collapse
|
22
|
Utami KH, Hillmer AM, Aksoy I, Chew EGY, Teo ASM, Zhang Z, Lee CWH, Chen PJ, Seng CC, Ariyaratne PN, Rouam SL, Soo LS, Yousoof S, Prokudin I, Peters G, Collins F, Wilson M, Kakakios A, Haddad G, Menuet A, Perche O, Tay SKH, Sung KWK, Ruan X, Ruan Y, Liu ET, Briault S, Jamieson RV, Davila S, Cacheux V. Detection of chromosomal breakpoints in patients with developmental delay and speech disorders. PLoS One 2014; 9:e90852. [PMID: 24603971 PMCID: PMC3946304 DOI: 10.1371/journal.pone.0090852] [Citation(s) in RCA: 34] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2013] [Accepted: 02/04/2014] [Indexed: 01/25/2023] Open
Abstract
Delineating candidate genes at the chromosomal breakpoint regions in the apparently balanced chromosome rearrangements (ABCR) has been shown to be more effective with the emergence of next-generation sequencing (NGS) technologies. We employed a large-insert (7-11 kb) paired-end tag sequencing technology (DNA-PET) to systematically analyze genome of four patients harbouring cytogenetically defined ABCR with neurodevelopmental symptoms, including developmental delay (DD) and speech disorders. We characterized structural variants (SVs) specific to each individual, including those matching the chromosomal breakpoints. Refinement of these regions by Sanger sequencing resulted in the identification of five disrupted genes in three individuals: guanine nucleotide binding protein, q polypeptide (GNAQ), RNA-binding protein, fox-1 homolog (RBFOX3), unc-5 homolog D (C.elegans) (UNC5D), transmembrane protein 47 (TMEM47), and X-linked inhibitor of apoptosis (XIAP). Among them, XIAP is the causative gene for the immunodeficiency phenotype seen in the patient. The remaining genes displayed specific expression in the fetal brain and have known biologically relevant functions in brain development, suggesting putative candidate genes for neurodevelopmental phenotypes. This study demonstrates the application of NGS technologies in mapping individual gene disruptions in ABCR as a resource for deciphering candidate genes in human neurodevelopmental disorders (NDDs).
Collapse
Affiliation(s)
- Kagistia H. Utami
- Human Genetics, Genome Institute of Singapore, Singapore, Singapore
- Department of Paediatrics, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore
| | - Axel M. Hillmer
- Cancer Therapeutics and Stratified Oncology, Genome Institute of Singapore, Singapore, Singapore
| | - Irene Aksoy
- Stem Cells and Developmental Biology, Genome Institute of Singapore, Singapore, Singapore
| | - Elaine G. Y. Chew
- Cancer Therapeutics and Stratified Oncology, Genome Institute of Singapore, Singapore, Singapore
| | - Audrey S. M. Teo
- Cancer Therapeutics and Stratified Oncology, Genome Institute of Singapore, Singapore, Singapore
| | - Zhenshui Zhang
- Cancer Therapeutics and Stratified Oncology, Genome Institute of Singapore, Singapore, Singapore
| | - Charlie W. H. Lee
- Computational and Mathematical Biology, Genome Institute of Singapore, Singapore, Singapore
| | - Pauline J. Chen
- Computational and Mathematical Biology, Genome Institute of Singapore, Singapore, Singapore
| | - Chan Chee Seng
- Scientific & Research Computing, Genome Institute of Singapore, Singapore, Singapore
| | - Pramila N. Ariyaratne
- Computational and Mathematical Biology, Genome Institute of Singapore, Singapore, Singapore
| | - Sigrid L. Rouam
- Computational and Mathematical Biology, Genome Institute of Singapore, Singapore, Singapore
| | - Lim Seong Soo
- Human Genetics, Genome Institute of Singapore, Singapore, Singapore
| | - Saira Yousoof
- Eye and Developmental Genetics Research, The Children’s Hospital at Westmead, Children’s Medical Research Institute and Save Sight Institute, Sydney, New South Wales, Australia
- Disciplines of Paediatrics and Child Health and Genetic Medicine, Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia
| | - Ivan Prokudin
- Eye and Developmental Genetics Research, The Children’s Hospital at Westmead, Children’s Medical Research Institute and Save Sight Institute, Sydney, New South Wales, Australia
- Disciplines of Paediatrics and Child Health and Genetic Medicine, Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia
| | - Gregory Peters
- Department of Cytogenetics, The Children’s Hospital at Westmead, Sydney, New South Wales, Australia
| | - Felicity Collins
- Department of Clinical Genetics, The Children’s Hospital at Westmead, Sydney, New South Wales, Australia
| | - Meredith Wilson
- Department of Clinical Genetics, The Children’s Hospital at Westmead, Sydney, New South Wales, Australia
| | - Alyson Kakakios
- Department of Immunology, The Children’s Hospital at Westmead, Sydney, New South Wales, Australia
| | | | - Arnaud Menuet
- Service de Genetique INEM UMR7355 CNRS-University, Centre Hospitalier Régional d’Orléans, Orléans, France
| | - Olivier Perche
- Service de Genetique INEM UMR7355 CNRS-University, Centre Hospitalier Régional d’Orléans, Orléans, France
| | - Stacey Kiat Hong Tay
- Department of Paediatrics, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore
| | - Ken W. K. Sung
- Computational and Mathematical Biology, Genome Institute of Singapore, Singapore, Singapore
| | - Xiaoan Ruan
- Genome Technology and Biology, Genome Institute of Singapore, Singapore, Singapore
| | - Yijun Ruan
- Genome Technology and Biology, Genome Institute of Singapore, Singapore, Singapore
| | - Edison T. Liu
- Cancer Therapeutics and Stratified Oncology, Genome Institute of Singapore, Singapore, Singapore
| | - Sylvain Briault
- Service de Genetique INEM UMR7355 CNRS-University, Centre Hospitalier Régional d’Orléans, Orléans, France
| | - Robyn V. Jamieson
- Eye and Developmental Genetics Research, The Children’s Hospital at Westmead, Children’s Medical Research Institute and Save Sight Institute, Sydney, New South Wales, Australia
| | - Sonia Davila
- Human Genetics, Genome Institute of Singapore, Singapore, Singapore
| | - Valere Cacheux
- Human Genetics, Genome Institute of Singapore, Singapore, Singapore
- * E-mail:
| |
Collapse
|
23
|
Perche O, Menuet A, Marcos M, Liu L, Pâris A, Utami KH, Kervran D, Cacheux V, Laudier B, Briault S. Combined deletion of two Condensin II system genes (NCAPG2 and MCPH1) in a case of severe microcephaly and mental deficiency. Eur J Med Genet 2013; 56:635-41. [PMID: 24013099 DOI: 10.1016/j.ejmg.2013.07.007] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2012] [Accepted: 07/29/2013] [Indexed: 01/13/2023]
Abstract
7qter deletion syndrome includes prenatal and/or postnatal growth retardation, microcephaly, psychomotor delay or mental retardation and a characteristic dysmorphism. If clinical features are well described, the molecular mechanisms underlying the 7qter deletion syndrome remain unknown. Those deletions usually arise de novo. Here, we describe a young boy with an abnormal phenotype consistent with a 7qter deletion syndrome. High resolution genomic analysis (Affymetrix Human Genome Wide SNP 6.0) revealed a 7q36.3 deletion encompassing NCAPG2, ESYT2, WDR60 and VIPR2, inherited from his asymptomatic father and paternal grandfather. In addition, the patient also harbored a MCPH1 deletion inherited from his healthy mother. Combined NCAPG2 and MCPH1 deletions were correlated with low mRNA levels and protein expression in the patient. MCPH1 and NCAPG2 proteins interaction is known to control chromosome structure and we thus propose that double heterozygosity for null mutations of those two genes of the Condensin II system contribute to mental deficiency with severe microcephaly phenotype.
Collapse
Affiliation(s)
- Olivier Perche
- UMR7355, CNRS, Orleans, France; Experimental and Molecular Immunology and Neurogenetics, University of Orleans, 3b rue de la Férollerie, 45071 Orleans Cedex 2, France; Genetic Department, Regional Hospital, 14 Avenue de l'Hôpital, 45100 Orleans, France
| | | | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Perche O, Haddad G, Menuet A, Callier P, Marcos M, Briault S, Laudier B. Dysregulation of FOXG1 pathway in a 14q12 microdeletion case. Am J Med Genet A 2013; 161A:3072-7. [PMID: 23956198 DOI: 10.1002/ajmg.a.36170] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/18/2013] [Accepted: 07/12/2013] [Indexed: 11/06/2022]
Abstract
"FOXG1 syndrome" includes postnatal microcephaly, severe intellectual disability with absence of language and agenesis of the corpus callosum. When the syndrome is associated with large 14q12q13 deletions, the patients present characteristic facial dysmorphism. Although all reports were based on genomic analysis, recently a FOXG1 regulatory elements deletion, associated with down regulated mRNA, suggested an implication of FOXG1 pathway. Herein, we report on a young boy with a phenotype consistent with a FOXG1 syndrome. He had a de novo translocation t(6;14)(q22.1;q12) associated with a heterozygous 14q12.2q13 deletion encompassing FOXG1. Subsequently, we investigated his transcriptomic profile on lymphoblastoïd cell lines and/or fibroblasts and showed that FOXG1 was commonly down-regulated. Moreover, several other FOXG1 pathway genes were also disturbed. Our data and review of previous reports highlight dysregulation of FOXG1 pathway as the cause of the "FOXG1 syndrome" developmental disorder.
Collapse
Affiliation(s)
- Olivier Perche
- UMR7355, CNRS, Orleans, France; Experimental and Molecular Immunology and Neurogenetics, University of Orleans, Orleans, France; Genetic Department, Regional Hospital, Orleans, France
| | | | | | | | | | | | | |
Collapse
|
25
|
Perche O, Vergnaud-Gauduchon J, Morand C, Dubray C, Mazur A, Vasson MP. Orange juice and its major polyphenol hesperidin consumption do not induce immunomodulation in healthy well-nourished humans. Clin Nutr 2013; 33:130-5. [PMID: 23602614 DOI: 10.1016/j.clnu.2013.03.012] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2012] [Revised: 03/19/2013] [Accepted: 03/19/2013] [Indexed: 01/30/2023]
Abstract
BACKGROUND & AIMS Polyphenols exert a variety of biological properties, including antioxidant, immunomodulatory and antigenotoxic effects. In a randomized crossover study in healthy men, we investigated the effects of orange juice and its major polyphenolic compound hesperidin on a panel of immune cell functions, including cytokine secretion by leukocytes, lytic activity of NK cells, and the Reactive Oxygen Species (ROS) burst by polymorphonuclear neutrophil cells (PMN). METHODS The protocol design was divided into three 4-week treatment periods separated by 3-week wash-out intervals, for total study duration of 18 weeks. During treatment periods, volunteers (n = 24) consumed daily 500 mL of orange juice, or an isocaloric control beverage with hesperidin (292 mg in a capsule), or of the same control beverage with a placebo. RESULTS Whatever the intake was, no variations were recorded on leukocyte subset distributions (PMN, B and T lymphocytes, NK cells and monocytes), ROS production by stimulated PMNs, lytic activity of NK cells or cytokine production capacity of leukocytes in well-nourished healthy volunteers. CONCLUSIONS We show that consumption within the usual daily intake range of orange juice and its major polyphenol hesperidin do not induce immunomodulation of cell immune function in healthy well-nourished humans.
Collapse
Affiliation(s)
- Olivier Perche
- Clermont Université, Université d'Auvergne, UMR 1019, Unité de Nutrition Humaine, CRNH-Auvergne, CLARA, BP 10448, F-63000 Clermont-Ferrand, France
| | - Juliette Vergnaud-Gauduchon
- Clermont Université, Université d'Auvergne, UMR 1019, Unité de Nutrition Humaine, CRNH-Auvergne, CLARA, BP 10448, F-63000 Clermont-Ferrand, France
| | - Christine Morand
- Centre de recherche INRA, UMR 1019 INRA Université d'Auvergne, Unité de Nutrition Humaine, Clermont-Ferrand Theix, France
| | - Claude Dubray
- CHU Clermont-Ferrand, Centre de Pharmacologie Clinique, Inserm, CIC 501, Univ Clermont 1, Faculté de Médecine, F-63001 Clermont-Ferrand, France
| | - Andrzej Mazur
- Centre de recherche INRA, UMR 1019 INRA Université d'Auvergne, Unité de Nutrition Humaine, Clermont-Ferrand Theix, France
| | - Marie-Paule Vasson
- Centre anticancéreux Jean-Perrin, CHU, Unité de Nutrition, CLARA, F-63000 Clermont-Ferrand, France.
| |
Collapse
|
26
|
Lamas B, Vergnaud-Gauduchon J, Goncalves-Mendes N, Perche O, Rossary A, Vasson MP, Farges MC. Altered functions of natural killer cells in response to L-Arginine availability. Cell Immunol 2012; 280:182-90. [PMID: 23399839 DOI: 10.1016/j.cellimm.2012.11.018] [Citation(s) in RCA: 60] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2012] [Revised: 10/03/2012] [Accepted: 11/29/2012] [Indexed: 01/09/2023]
Abstract
L-Arginine (L-Arg) availability is crucial in the regulation of immune response. Indeed, L-Arg deficiency induces T-cell dysfunction and could modulate the properties of natural killer (NK) cells involved in the early host defense against infections and tumors. We explored the impact of L-Arg depletion on NK cell functions using two models - an NK-92 cell line and isolated human blood NK cells. Below 5mg/L of L-Arg, NK-92 cell proliferation was decreased and a total L-Arg depletion reduced NK-92 cell viability. NK cell cytotoxicity was significantly inhibited in presence of low L-Arg concentration (2.5 mg/L). L-Arg depletion reduced the expression of NK-92 activating receptors, NKp46 and NKp30, the expression of NK ζ chain and the NK-92 intracellular production of IFN-γ. Whatever the L-Arg concentrations tested, no significant variation in the gene expression of transporters and enzymes involved in L-Arg metabolism was found. Thus, L-Arg availability modulates the phenotypic and functional properties of NK cells.
Collapse
Affiliation(s)
- Bruno Lamas
- Clermont Université, Université d'Auvergne, EA 4233, Nutrition Cancerogenèse et Thérapie anti-tumorale, CLARA, CRNH Auvergne, Clermont-Ferrand, France.
| | | | | | | | | | | | | |
Collapse
|
27
|
Perche O, Laudier B, Menuet A, Odent S, Laumonnier F, Briault S. FG syndrome: The FGS2 locus revisited. Am J Med Genet A 2012; 158A:1489-92. [DOI: 10.1002/ajmg.a.35322] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2011] [Accepted: 01/09/2012] [Indexed: 11/08/2022]
|
28
|
Perche O, Lainé MC, Pageaux JF, Laugier C, Sandoz D. Modification of cell evagination and cell differentiation in quail oviduct hyperstimulated by progesterone. Biol Cell 2012. [DOI: 10.1111/j.1768-322x.1989.tb00854.x] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
29
|
Pageaux JF, Dufrene L, Laugier C, Perche O, Sandoz D. Heterogeneity of progesterone receptor expression in epithelial cells of immature and differentiating quail oviduct. Biol Cell 2012. [DOI: 10.1111/j.1768-322x.1989.tb00855.x] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
30
|
Bellocq JP, Grizeau B, Anger E, Chenard MP, Fléjou JF, Guiu M, Heresbach N, Mehay H, Michiels JF, Ounnoughene M, Perche O, Saint-André JP. [Accreditation and pathologic anatomy and cytology]. Ann Pathol 2010; 30:97-9. [PMID: 21055559 DOI: 10.1016/j.annpat.2010.08.001] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/02/2010] [Accepted: 08/03/2010] [Indexed: 11/25/2022]
Affiliation(s)
- Jean-Pierre Bellocq
- Département de pathologie, hôpitaux universitaires de Strasbourg, 1 avenue Molière, Strasbourg, France.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
31
|
Abstract
PURPOSE To study the apoptotic mechanism involved in our model of light-induced retinal degeneration. METHODS Rats were injected intravitreally with PBS, 2% dimethyl sulfoxide (DMSO), caspase inhibitor Z-VAD-FMK (1.06 mM), Z-YVAD-FMK (0.16 mM), or Z-DEVD-FMK (2 mM) before they were placed in constant light (3400 lux) for 24 hours. Additional controls included rats that were uninjected or were punctured with a dry needle. Electroretinograms were recorded before injection and 1 day after the cessation of exposure to constant light. A group of rats was killed for apoptotic cell detection in the outer nuclear layer. Fifteen days later, the remaining rats were killed for histology, and the outer nuclear layer (ONL) thickness was measured. Caspase-1, caspase-3, and calpain activities were measured before and 1 day after exposure to the damaging light. RESULTS ZVAD, YVAD, and DEVD inhibited caspase-1 and -3 activities, but not calpain activity, from the beginning and up to 1 day after light exposure. In untreated, dry needle-punctured, PBS, DMSO, and YVAD groups, light exposure significantly reduced retinal function and ONL thickness and increased by 51-fold the number of apoptotic cells. ZVAD and DEVD preserved retinal function to 86% and 78%, respectively, and reduced by three times the number of apoptotic photoreceptors. ONL thickness was more preserved in ZVAD (to 72%) than in DEVD (to 56%). CONCLUSIONS In the authors' model of retinal degeneration, photoreceptor cells die through a caspase-dependent mechanism. However, the molecular events involved during and after light exposure seemed to implicate different proteases.
Collapse
Affiliation(s)
- Olivier Perche
- Laboratoire de Biophysique Sensorielle, Université Clermont 1, Clermont-Ferrand, France.
| | | | | |
Collapse
|
32
|
Perche O, Hayashi M, Hayashi K, Birk D, Trelstad RL, Sandoz D. Origin of type I collagen localized within oviduct epithelium of quail hyperstimulated by progesterone. J Cell Sci 1990; 95 ( Pt 1):85-95. [PMID: 2351704 DOI: 10.1242/jcs.95.1.85] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Bird oviduct development is controlled by sex steroid hormones. Estrogens (E) induce cell proliferation, formation of tubular glands by epithelial cell evagination and cell differentiation. Progesterone (P) strongly increases secretory processes in E-treated quails, but inhibits cell proliferation and cell evagination. The balance between E and P is very critical for the development and morphogenesis of the oviduct. After six daily injections of low doses of E (10 micrograms day-1) and high doses of P (5 mg day-1) into ovariectomized quails, cell proliferation and secretory process are stimulated but cell evagination is totally inhibited and distribution of striated collagen is perturbed. Using antibodies against type I collagen the stroma, which is mainly composed of fibroblasts, is brightly stained, as are some regions within the epithelium. Electron microscopy shows that bundles of striated collagen fibrils appear in extracellular spaces between the lateral membranes of the epithelial cells or between the basal lamina and the epithelial basal membrane. After in situ hybridization using a 35S riboprobe specific for mRNA of the alpha 2 chain of type I collagen, mRNA was detected only in the fibroblasts of the stroma and not in epithelial cells. Furthermore electron microscope studies of collagen bundles in serial sections clearly show collagen fibrils passing through the basal lamina. It is assumed that the type I collagen between epithelial cells originates from mesenchymal cells. In the oviduct of immature birds or after physiological E + P stimulation, striated collagen is localized only in the stroma and never within the epithelium. These results indicate a modulation of extracellular matrix by sex steroid hormones in the quail oviduct.
Collapse
Affiliation(s)
- O Perche
- Laboratoire de Biologie Cellulaire CNRS, Ivry sur Seine, France
| | | | | | | | | | | |
Collapse
|
33
|
Perche O, Sandoz D. Immunolocalization of laminin during estrogen-induced differentiation of quail oviduct epithelial cells. Biol Cell 1988; 64:353-62. [PMID: 3067807 DOI: 10.1016/0248-4900(88)90009-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
During estrogen-induced development of the quail oviduct, tubular glands are formed by evagination of epithelial cells into the stroma. The distribution of laminin was studied during the early stages by means of immunofluorescence and immunoperoxidase techniques. Ultrastructural changes in the basal lamina were studied by electron microscopy. Basement membranes at all stages of development were delineated with 3 polyclonal antilaminin antisera. However, in ovariectomized birds, laminin could not be detected by one of the polyclonal antilaminin antisera. Subsequently, this antibody detected laminin as epithelial cell evaginations were induced by estradiol benzoate. The heavy and light chains of Engelbreth Holm sarcoma (EHS) laminin were revealed in immunoblotting by all antibodies. By electron microscopy after the immunoperoxidase technique with antilaminin antisera laminin appears to be accumulated mainly in the lamina densa. Furthermore, the thickness of the basal lamina increases during oviduct development. These data indicate that basal lamina organization is modified during oviduct cell differentiation and that immunoreactivity of epithelial basement membrane laminin changes during development.
Collapse
Affiliation(s)
- O Perche
- Centre de Biologie Cellulaire CNRS, Ivry-sur-Seine, France
| | | |
Collapse
|